A Phase II, 2-stage, 2-arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Latest Information Update: 14 Feb 2022
At a glance
- Drugs MK 2206 (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 04 Aug 2017 Status changed from active, no longer recruiting to completed.
- 04 Aug 2017 Status changed from active, no longer recruiting to completed.
- 19 Mar 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (NCT01307631).